SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 20.03-1.1%Oct 30 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: flatsville who wrote (297)2/12/2002 9:05:53 AM
From: Dorine Essey  Read Replies (1) of 340
 
Nessuah Zannex: Further Teva acquisition in pipeline

Globes' corespondent
12.02.2002 11:56

In a report issued ahead of the publication of Teva's (Nasdaq: TEVA) 2001 results on Thursday, Nessuah Zannex says that it expects the completion of the purchase of Bayer Classic within a few weeks, “with a further significant acquisition in the pipeline.”
Nessuah Zannex reiterates its “Buy” recommendation for the share, with a twelve month price target of $79. Teva closed at $59.66 on Wall Street yesterday.

The report predicts that Teva will show revenue of $2,055.6 million for 2001, 17.5% more than in 2000. Nessuah Zannex’s profit projection is $284.6 million, 88% above the 2000 figure. This gives an EPS of $2.07 (fully diluted), above the market consensus of $2.05, Nessuah Zannex says.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News